Evidence map›Paper›PMID 33027419›Full record

ArticleMemorias do Instituto Oswaldo Cruz2020

Flavonoid glycosides and their putative human metabolites as potential inhibitors of the SARS-CoV-2 main protease (Mpro) and RNA-dependent RNA polymerase (RdRp).

Felipe Moura A da Silva, Katia Pacheco A da Silva, Luiz Paulo M de Oliveira, Emmanoel V Costa, Hector Hf Koolen, Maria Lúcia B Pinheiro, Antonia Queiroz L de Souza, Afonso Duarte L de Souza

Open access · diamondAbstract read
In one paragraph

Article in Memorias do Instituto Oswaldo Cruz, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed
11.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 101 citations in OpenAlex.

  1. Evaluation of the Pharmacological Potential ofPharmaceuticals (Basel, Switzerland) · 2026
    Article
  2. Article
  3. Heliyon · 2024
    Article
  4. InBiochemistry and biophysics reports · 2024
    Article
  5. Review
  6. Review
  7. Discovery of Pyrano[2,3-Pharmaceuticals (Basel, Switzerland) · 2024
    Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Review
  14. The effect ofSaudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2023
    Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Felipe Moura A da SilvaUniversidade Federal do Amazonas, Centro de Apoio Multidisciplinar, Central Analítica, Manaus, AM, Brasil.ORCID http://orcid.org/0000-0002-1809-1372
Katia Pacheco A da SilvaSecretaria Municipal de Saúde, Prefeitura de Itabirito, Itabirito, MG, Brasil.
Luiz Paulo M de OliveiraUniversidade Federal do Amazonas, Centro de Apoio Multidisciplinar, Central Analítica, Manaus, AM, Brasil.
Emmanoel V CostaUniversidade Federal do Amazonas, Departamento de Química, Manaus, AM, Brasil.
Hector Hf KoolenUniversidade do Estado do Amazonas, Grupo de Pesquisa em Metabolômica e Espectrometria de Massas, Manaus, AM, Brasil.
Maria Lúcia B PinheiroUniversidade Federal do Amazonas, Centro de Apoio Multidisciplinar, Central Analítica, Manaus, AM, Brasil.
Antonia Queiroz L de SouzaUniversidade Federal do Amazonas, Centro de Apoio Multidisciplinar, Central Analítica, Manaus, AM, Brasil.
Afonso Duarte L de SouzaUniversidade Federal do Amazonas, Centro de Apoio Multidisciplinar, Central Analítica, Manaus, AM, Brasil.ORCID http://orcid.org/0000-0001-7007-3991
Universidade Federal do Amazonas · BRSecretaria Municipal de Saúde · BRUniversidade do Estado do Amazonas · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSince the World Health Organization (WHO) declared Coronavirus disease 2019 (COVID-19) to be a pandemic infection, important severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) non-structural proteins (nsp) have been analysed as promising targets in virtual screening approaches. Among these proteins, 3-chymotrypsin-like cysteine protease (3CLpro), also named main protease, and the RNA-dependent RNA polymerase (RdRp), have been identified as fundamental targets due to its importance in the viral replication stages.

objectivesTo investigate, in silico, two of the most abundant flavonoid glycosides from Dysphania ambrosioides; a medicinal plant found in many regions of the world, along with some of the putative derivatives of these flavonoid glycosides in the human organism as potential inhibitors of the SARS-CoV-2 3CLpro and RdRp.

methodsUsing a molecular docking approach, the interactions and the binding affinity with SARS-CoV-2 3CLpro and RdRp were predicted for quercetin-3-O-rutinoside (rutin), kaempferol-3-O-rutinoside (nicotiflorin) and some of their glucuronide and sulfate derivatives.

findingsDocking analysis, based on the crystal structure of 3CLpro and RdRp, indicated rutin, nicotiflorin, and their glucuronide and sulfate derivatives as potential inhibitors for both proteins. Also, the importance of the hydrogen bond and π-based interactions was evidenced for the presumed active sites. MAIN

conclusionsOverall, these results suggest that both flavonoid glycosides and their putative human metabolites can play a key role as inhibitors of the SARS-CoV-2 3CLpro and RdRp. Obviously, further researches, mainly in vitro and in vivo experiments, are necessary to certify the docking results reported here, as well as the adequate application of these substances. Furthermore, it is necessary to investigate the risks of D. ambrosioides as a phytomedicine for use against COVID-19.

Indexed as

BetacoronavirusCoronavirus 3C ProteasesCoronavirus InfectionsCOVID-19Cysteine EndopeptidasesFlavonoidsGlycosidesHumansMolecular Docking SimulationPandemicsPneumonia, ViralRNA-Dependent RNA PolymeraseSARS-CoV-2Viral Nonstructural ProteinsCoronavirus 3C ProteasesCysteine EndopeptidasesFlavonoidsGlycosidesRNA-Dependent RNA PolymeraseViral Nonstructural Proteins

Identifiers

PMID33027419
PMCPMC7534957
OpenAlexW3089536260

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.